Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 31 of 37 for:    Acerta Pharma

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02029443
Recruitment Status : Active, not recruiting
First Posted : January 8, 2014
Last Update Posted : February 1, 2019
Sponsor:
Information provided by (Responsible Party):
Acerta Pharma BV

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : January 2021
Study Completion Date : No date given